OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer
Stephen P. Hack, Wendy Verret, Sohail Mulla, et al.
Therapeutic Advances in Medical Oncology (2021) Vol. 13
Open Access | Times Cited: 34
Stephen P. Hack, Wendy Verret, Sohail Mulla, et al.
Therapeutic Advances in Medical Oncology (2021) Vol. 13
Open Access | Times Cited: 34
Showing 26-50 of 34 citing articles:
Treatment of biliary tract carcinoma over the last 30 years
Yutaka Midorikawa
BioScience Trends (2022) Vol. 16, Iss. 3, pp. 189-197
Open Access | Times Cited: 4
Yutaka Midorikawa
BioScience Trends (2022) Vol. 16, Iss. 3, pp. 189-197
Open Access | Times Cited: 4
Atezolizumab: an investigational agent for the treatment of biliary tract cancer
Stephen P. Hack, Andrew X. Zhu
Expert Opinion on Investigational Drugs (2021) Vol. 30, Iss. 10, pp. 1007-1015
Closed Access | Times Cited: 4
Stephen P. Hack, Andrew X. Zhu
Expert Opinion on Investigational Drugs (2021) Vol. 30, Iss. 10, pp. 1007-1015
Closed Access | Times Cited: 4
Immunotherapy
Layal Al Mahmasani, James J. Harding, Ghassan K. Abou‐Alfa
Hematology/Oncology Clinics of North America (2024) Vol. 38, Iss. 3, pp. 643-657
Closed Access
Layal Al Mahmasani, James J. Harding, Ghassan K. Abou‐Alfa
Hematology/Oncology Clinics of North America (2024) Vol. 38, Iss. 3, pp. 643-657
Closed Access
Therapeutic yield of extensive molecular profiling in cholangiocarcinoma: a retrospective single-center study
Justine Vancanneyt, Bie Wilmsen, Caroline Luyten, et al.
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 11, pp. 9173-9181
Open Access | Times Cited: 1
Justine Vancanneyt, Bie Wilmsen, Caroline Luyten, et al.
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 11, pp. 9173-9181
Open Access | Times Cited: 1
Clinical research progress of targeted therapy combined with immunotherapy for advanced cholangiocarcinoma
Qin Liu, Yuanyuan Chen, Yan Hu, et al.
Cancer Treatment and Research Communications (2023) Vol. 37, pp. 100771-100771
Open Access | Times Cited: 1
Qin Liu, Yuanyuan Chen, Yan Hu, et al.
Cancer Treatment and Research Communications (2023) Vol. 37, pp. 100771-100771
Open Access | Times Cited: 1
Immune microenvironment and progress in immunotherapy of cholangiocarcinoma
Xinyu Shao
Clinical Immunology Communications (2023) Vol. 4, pp. 73-78
Open Access
Xinyu Shao
Clinical Immunology Communications (2023) Vol. 4, pp. 73-78
Open Access
Therapeutic yield of extensive molecular profiling in cholangiocarcinoma: a retrospective single center study.
Justine Vancanneyt, Bie Wilmsen, Caroline Luyten, et al.
Research Square (Research Square) (2023)
Open Access
Justine Vancanneyt, Bie Wilmsen, Caroline Luyten, et al.
Research Square (Research Square) (2023)
Open Access
Gemcitabine and cisplatin or oxaliplatin chemotherapy combined with atezolizumab plus bevacizumab for advanced biliary tract cancers: a single-arm trial
Kang Wang, Hongming Yu, Yan‐Jun Xiang, et al.
Future Oncology (2023) Vol. 19, Iss. 15, pp. 1029-1035
Closed Access
Kang Wang, Hongming Yu, Yan‐Jun Xiang, et al.
Future Oncology (2023) Vol. 19, Iss. 15, pp. 1029-1035
Closed Access
Immunotherapies in Biliary Tract Cancers: The Current Landscape
Chao Yin, Ali Alqhatani, Aiwu Ruth He
(2022), pp. 1-28
Closed Access
Chao Yin, Ali Alqhatani, Aiwu Ruth He
(2022), pp. 1-28
Closed Access
